GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos de Lisboa in Libson, Portugal.

Read the full story.